Adamis To Resubmit NDA For ZIMHI Within 45 Days - Quick Facts

Adamis Pharmaceuticals Corporation (ADMP) issued an update on the status of the NDA for ZIMHI high-dose naloxone injection product for the treatment of opioid overdose. The company had a Type A meeting with the FDA to review comments on the additional information provided by the company in response to the FDA's Complete Response Letter. Adamis said it believes the meeting was productive and plans to resubmit the NDA for ZIMHI to the FDA within the next 45 days.

Dennis Carlo, CEO of Adamis Pharmaceuticals, said: "We believe we obtained critical feedback from the FDA at our Type A meeting on a number of issues and also received an acknowledgement of the agency's intention to commit to a rapid review of the NDA."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Pentagon announced that up to $9 billion worth of cloud-computing contracts were awarded to Google, Oracle, Amazon, and Microsoft. In a statement, the U.S. Department of Defense said, "The purpose of this contract is to provide the Department of Defense with enterprise-wide, globally available cloud services across all security domains and classification levels..." Juul Labs, an e-cigarette maker, said it has reached settlements with more than 5,000 vaping lawsuits in the United States. The cases were related to personal injury, consumer class action, government entity, and Native American tribes. In a statement, the company said it cannot disclose the settlement amount at this time as part of the settlement and court process. Apple Inc. plans to start using American-made processors from the new advanced chip factory in Phoenix, Arizona operated by chip giant Taiwan Semiconductor Manufacturing Co., according to its Chief Executive Officer Tim Cook. At an event in the factory in Arizona, which was attended by U.S. President Joe Biden, it was also announced that TSMC will invest $40 billion in the new factory.
Follow RTT